Full Breakdown
White House to Unveil New Drug-Pricing Deals with Mid-Size Biotech Firms
8/27/2026, 1:23:12 AM
New Agreements Target Medicaid Drug Costs
Bloomberg News, citing sources familiar with the matter, reports that President Donald Trump’s administration will announce a fresh round of drug-pricing agreements with midsize biotechnology companies on Monday. The deals would require participating firms to extend outpatient-drug discounts to state Medicaid programs so that the prices states pay match the companies’ pricing in foreign markets. No specific biotech firms were identified in the report.
Background on Prior Voluntary Pricing Deals
The administration has previously secured voluntary agreements with 17 pharmaceutical companies, including Pfizer, Eli Lilly and Amgen, to lower medication costs for Medicaid and cash-pay patients. Those earlier accords also produced price reductions for GLP-1 drugs and expanded Medicare coverage for obesity treatments. President Trump has repeatedly pressured drugmakers to bring U.S. prices in line with those abroad.
Expected Savings and Scope
The administration estimates that the new agreements will generate $64.3 billion in combined federal and state savings over the next ten years. U.S. patients currently pay, on average, nearly three times more for prescription medicines than consumers in other developed nations, underscoring the potential fiscal impact of the proposed discounts.
Official Position and Rationale
The administration frames the initiative as a continuation of its broader effort to curb what it describes as excessive drug pricing.
Potential Impact on Patients and State Budgets
If implemented, the agreements could lower out-of-pocket costs for Medicaid beneficiaries and reduce state expenditures on prescription drugs. However, the lack of disclosed participating companies leaves uncertainty about which specific therapies will be affected and how quickly savings will materialize.
